Kingswood Wealth Advisors LLC Sells 22,228 Shares of Johnson & Johnson (NYSE:JNJ)

Kingswood Wealth Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 61.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,150 shares of the company's stock after selling 22,228 shares during the period. Kingswood Wealth Advisors LLC's holdings in Johnson & Johnson were worth $2,046,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Vinva Investment Management Ltd grew its holdings in Johnson & Johnson by 6.8% in the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock valued at $17,988,000 after purchasing an additional 7,110 shares during the last quarter. Financial Counselors Inc. boosted its position in Johnson & Johnson by 5.3% during the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock worth $29,996,000 after acquiring an additional 9,309 shares during the last quarter. Meridian Investment Counsel Inc. grew its position in shares of Johnson & Johnson by 19.6% in the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock valued at $3,667,000 after purchasing an additional 3,710 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Johnson & Johnson by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock worth $2,858,543,000 after acquiring an additional 102,502 shares during the last quarter. Finally, Lord Abbett & CO. LLC acquired a new position in Johnson & Johnson during the third quarter valued at approximately $69,859,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on JNJ shares. Barclays raised their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a report on Tuesday. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Bank of America lowered their price objective on Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada restated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Finally, Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $170.44.

Johnson & Johnson Trading Up 1.8 %

JNJ traded up $2.74 during midday trading on Thursday, reaching $153.89. 3,563,013 shares of the company were exchanged, compared to its average volume of 9,399,796. The stock has a market capitalization of $370.51 billion, a P/E ratio of 23.14, a PEG ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock's 50-day simple moving average is $147.73 and its 200 day simple moving average is $156.10. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same quarter in the prior year, the business posted $2.29 EPS. The business's revenue was up 5.3% compared to the same quarter last year. As a group, analysts forecast that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.22%. Johnson & Johnson's payout ratio is 74.59%.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the company's stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.